[O-29] Oral Session 29
Neuroimmunology 3 E

[O-29-8] Pooled safety analysis from Phase 3 trials of satralizumab in neuromyelitis optica spectrum disorder

^○Kazuo Fujihara¹, Benjamin Greenberg², Jerome De Seze³, Edward Fox⁴, Albert Saiz⁵, Takashi Yamamura⁶, Carole Marcillat⁷, Xiujing Kou⁷, Kristina Weber⁷, Brian G. Weinshenker⁸ (1.Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Japan, 2.University of Texas Southwestern Medical Center, 3.Department of Neurology, Hôpital de Hautepierre INSERM, 4.Central Texas Neurology Consultants, 5.Service of Neurology, University of Barcelona, 6.National Institute of Neuroscience, National Center of Neurology and Psychiatry, 7.F. Hoffmann-La Roche Ltd, 8.Department of Neurology, Mayo Clinic)